Around the world, more bacterial infections are growing resistant to standard antibiotics, making them harder to treat. Antimicrobial resistance is especially dangerous for critically ill newborns, infants and young children,

Neonatal sepsis remains one of the leading causes of newborn death and long-term neurodevelopmental impairment worldwide, particularly across resource-limited settings. Tackling it demands research that is collaborative, adaptive, and connected across

Following the successful launch of its flagship Neonatal Sepsis Course, the Severe Neonatal Infection Adaptive Platform Trials in Africa (SNIP-AFRICA) Consortium is now inviting applications for the second cohort of

Neonatal sepsis remains one of the leading causes of newborn death in sub-Saharan Africa. Tackling it requires not just better diagnosis and management, but a generation of clinicians and researchers

SNIP-AFRICA has launched its flagship Neonatal Sepsis Course, an important step forward in strengthening clinical care and research capacity for newborn health in sub-Saharan Africa. The first cohort of delegates

A paper published in the journal Antimicrobial Agents and Chemotherapy (AAC) reports that off-patent antibiotics, fosfomycin and flomoxef, when used at standard doses, were safe in newborn babies with suspected

Meaningful engagement of parents and caregivers, especially those with lived experience of newborn health challenges, is increasingly recognised as crucial for improving care, shaping research priorities, and ensuring interventions meet

Seven neonatal intensive care units across Ghana, Kenya, South Africa, Tanzania and Uganda have begun a two-year surveillance programme to monitor neonatal sepsis and antimicrobial resistance (AMR). The programme, which

Children are among the most vulnerable populations in clinical research. Conducting ethical paediatric clinical trials requires a careful balance between advancing medical knowledge and protecting the rights and welfare of

SNIP-AFRICA is pleased to announce a major milestone in the fight against neonatal sepsis: the launch of the NeoSep1 clinical trial, which enrolled its first newborn last week at Tygerberg